Latest Ratios: P/E Ratio -3.8x · EV/EBITDA N/A · ROE -776.9%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $251M | $405M | $218M | $140M | $279M | $887M | $205M | $7M | $3M | $46M | $24M |
| Enterprise Value | $265M | $420M | $192M | $108M | $208M | $796M | $184M | $1M | $-12039999 | $40M | $-7116635 |
| P/E Ratio → | -3.84 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 52.45 | 91.83 | 53.80 | 23.28 | 112.13 | — | 4776.56 | — | — | — | — |
| P/B Ratio | — | — | 7.36 | 3.46 | 3.77 | 9.26 | 9.53 | 0.66 | — | — | 1.77 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 95.13 | 47.38 | 17.89 | 83.52 | — | 4275.42 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 45.9% | 51.5% | 88.3% | 100.0% | — | -14676.7% | — | — | — | — |
| Operating Margin | -1425.7% | -1425.7% | -1350.4% | -1085.7% | -3580.0% | — | -49500.0% | — | — | — | — |
| Net Profit Margin | -1537.4% | -1537.4% | -1333.0% | -1045.0% | -3488.9% | — | -50748.8% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -776.9% | -776.9% | -154.0% | -110.1% | -102.2% | -99.5% | -134.0% | -383.4% | — | -2297.9% | -77.6% |
| ROA | -107.7% | -107.7% | -73.5% | -72.8% | -81.0% | -87.7% | -98.8% | -118.3% | -60.7% | -112.1% | -44.5% |
| ROIC | -1565.6% | -1565.6% | -704.2% | -907.2% | -1920.2% | -2088.8% | -640.7% | — | — | — | — |
| ROCE | -154.7% | -154.7% | -101.1% | -102.7% | -99.6% | -94.7% | -118.2% | -105.6% | -276.4% | -130.8% | -98.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.10 | 0.17 | 0.09 | 0.03 | 0.12 | 0.13 | — | — | 0.06 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.88 | -0.80 | -0.96 | -0.96 | -1.00 | -0.55 | — | — | -2.30 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.08 | -12.08 | — | — | — | -738.46 | -19.81 | -8.01 | -88.77 | -197.12 | -217.47 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | 1.06 | 2.86 | 2.51 | 3.45 | 14.66 | 7.16 | 3.47 | 5.71 | 2.15 | 6.20 |
| Quick Ratio | 1.06 | 1.06 | 2.86 | 2.51 | 3.45 | 14.66 | 7.16 | 3.47 | 5.71 | 2.15 | 6.20 |
| Cash Ratio | 0.81 | 0.81 | 2.71 | 2.31 | 3.19 | 13.57 | 6.65 | 1.64 | 5.41 | 2.10 | 6.17 |
| Asset Turnover | — | 0.10 | 0.05 | 0.09 | 0.02 | — | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $300M | $271M | $244M | $215M | $195M | $112M | $14M | $618182 | $377837 | $239824 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OCGN stock.
Ocugen, Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
Ocugen, Inc.'s return on equity (ROE) is -776.9%. The historical average is -131.2%.
Based on historical data, Ocugen, Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ocugen, Inc. has 45.9% gross margin and -1425.7% operating margin.
Key Metrics
Top Statement Risk
Debt-funded burn against negative equity
Metrics are mathematically derived from official filings.
Sales Multiple Prices Commercialization Not Yet Earned
At roughly 58 times sales, Ocugen's equity pricing embeds expectations far beyond its current $1.5M quarterly revenue base, while the negative trailing P/E reflects losses rather than cheapness; per recent SEC filings, no EV/EBITDA, forward P/E or P/FCF multiple can be computed.
The 58.20x P/S appears to be a denominator artifact as much as a growth premium — sales of roughly $6M annualized against a market price that implies commercial-scale economics, a framing that would require revenue inflection of an order of magnitude. The -3.29 trailing P/E should not be read as a deep-value signal; it is simply a loss-making numerator, and with EV/EBITDA unavailable because EBITDA is negative, investors are effectively pricing pipeline optionality rather than reported fundamentals. Relative to gene-therapy peers such as NTLA and CRSP trading at 1.98x–2.41x sales, Ocugen's multiple suggests the market is assigning it a premium position it has not yet demonstrated in filings.
Zero-COGS Distorts Margin Quality Reads
Gross margin printed 100.0% in every one of the ten reported quarters because cost of goods is recorded at zero, leaving operating margin of -11.1% and net margin of -16.7% in 2026Q2 as the only meaningful profitability reads, according to Ocugen's reported figures.
The uniform 100% gross margin conveys no pricing power or manufacturing efficiency, so true earning power has to be judged at the operating line, where losses have widened from -$12.2M in 2024Q1 to -$16.4M in 2026Q2 against only $1.5M of revenue. The 2025Q4 prints of +88.1% operating margin and +91.7% net margin are outliers that likely reflect non-recurring items rather than a business inflection, and analysts should treat them as noise in any margin-trend regression. The consistent pattern of net margin trailing operating margin — including the -$24.9M net loss against a -$16.4M operating loss in 2026Q2 — suggests below-line charges are recurring enough to matter in any normalized earnings estimate.
Improving ROIC Reflects Asset Growth, Not Returns
ROIC improved to -2.8% by 2026Q1 from -160.4% in 2025Q1, yet the improvement appears to track balance-sheet expansion rather than recovering earning power; as reported in Ocugen's filings, ROA of -27.5% and uncomputable ROE confirm the asset base is still value-destructive.
The dramatic ROIC swing from triple-digit negatives toward single-digit negatives looks like compounding improvement in isolation, but asset turnover of 0.02–0.03 across the window shows the larger asset base — total assets rising to $124.2M — is not yet generating commensurate revenue. With equity now negative, ROE ceased to be meaningful after 2026Q1, which itself signals that the denominator has been exhausted by cumulative retained losses of roughly -$452M. On a ten-quarter view, Ocugen appears to be decaying returns on capital rather than compounding them, and any thesis premised on operating leverage would need evidence of revenue scaling before this ratio turns informative.
Debt Surge Outpaces Any Coverage Capacity
Ocugen's debt-to-equity ratio of 5.74 in 2026Q1 became uncomputable thereafter as total debt jumped to $86.3M in 2026Q2 against negative equity of -$16.6M, while interest coverage of -4.56 in the latest quarter signals no earnings cushion for debt service, per recent SEC filings.
The step-up in leverage from a D/E of 0.23–0.41 in early-to-mid 2024 to a structurally unmeasurable position in 2026Q2 represents a genuine capital-structure shift, and because coverage has been negative in every quarter with data, refinancing or repayment capacity appears to rest on capital-market access rather than operating cash generation. Investors should note that interest coverage deteriorating from -13.53 to -4.56 is not an improvement in comfort — it mathematically reflects a smaller loss relative to interest, likely because interest expense rose with the new debt rather than earnings recovering. Given cumulative operating outflows of $133.6M over ten quarters, the debt trajectory warrants close monitoring of maturity profiles and any covenant terms disclosed in filings.
Cash Balance Masks Sub-1.0 Current Ratio
The current ratio slipped to 0.80 in 2026Q2, the first sub-1.0 print in ten quarters, even as cash climbed to $100.1M; the identical quick ratio of 0.80 confirms the shortfall is not inventory-driven, based on Ocugen's reported balance sheets.
A cash balance of roughly $100M alongside a sub-1.0 current ratio is an unusual combination and implies that near-term obligations expanded in tandem with the $53M quarterly debt increase — a pattern consistent with debt draws carrying current maturities, though this warrants confirmation against the filings. Under severe stress, the company's asset-light profile (capex of only about $3.65M over ten quarters) means the burn is largely personnel and R&D, which is theoretically deferrable, but the negative equity position removes conventional balance-sheet flexibility. Relative to its own history — current ratios of 2.58–2.86 in late 2024 — the deterioration is material and appears to be driven by liability-side growth rather than asset-side shrinkage.
Price-to-Sales Misreads Pre-Revenue Economics
Price-to-sales is the most commonly misapplied ratio here: at 58.20x it implies operating leverage a zero-COGS, sub-$2M quarterly revenue model cannot yet deliver, obscuring the cash-burn and equity-erosion trajectory that should anchor any realistic valuation, according to Ocugen's reported financials.
For a pre-commercial biotech, P/S invites the assumption that scale revenue will flow through a mostly fixed cost base into earnings, but Ocugen's operating expenses of $17.9M per quarter dwarf revenue by roughly 12 to 1, and the burn has widened from -$11.4M per quarter in 2024 to -$17.2M in 2026 year-to-date. Cash burn per dollar of market value, dilution-adjusted equity value relative to remaining cash runway, and implied financing need are more discriminating metrics, because they capture the real risk that future shareholders absorb the economics. Analysts should treat the reported 2025Q4 FCF margin of +72.5% alongside -$14.0M of free cash flow as internally inconsistent data requiring verification before any margin-based extrapolation, and focus instead on the persistent negative free cash flow visible in every other quarter.